About David Weiner
David Weiner, MD, is chief scientific officer of 28bio. He is also co-chairman of the company's board. 28bio makes CNS-3D Brain Organoids, which it tests as a predictor of seizure risk from small molecule drugs.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name David Weiner in the role, so the role may have started earlier or lasted longer.
28bio, Inc. Current
Chief Scientific Officer and director
Co-chairman of the Board
2024 – Present · Metairie, LA
Brain organoids made from human cells show drug developers how a candidate may affect patients before it reaches the clinic.
Key Colleagues at Startups
The people David Weiner works with at each company, as listed on that company's latest Form D.
28bio, Inc. · Form D/A, Oct 29, 2026
Alif Saleh
Chief Executive Officer and director
DP
Dale Pfost
Director
MK
Michael Katz
Director
MK
Miklos Kobor
Director
Paul Friel
Director